Patient characteristics
| Number of study patients | 71 |
| Median age, y (range) | 8.0 (0.6-23.1) |
| Median follow-up after transplantation, y (range) | 1.5 (0.1-4.3) |
| Disease status xabefore transplantation, n | |
| CR1 | 23 |
| CR2 | 29 |
| CR > 2 | 2 |
| NR | 17 |
| Donor, n | |
| MSD | 23 |
| MUD | 31 |
| MMFD | 17 |
| Stem-cell source, n | |
| BM | 45 |
| PB | 23 |
| Other | 3 |
| T-cell depletion, n | |
| Yes | 15 |
| No | 56 |
| Myeloablative conditioning regimen, n | |
| Busulfan-based | |
| Bus + Cyc + Mel ± ATG, n | 34 |
| Bus + Cyc ± ATG | 9 |
| Other (TBI/treosulfan-based) | 4 |
| RIC, n | |
| Flu + Thio + Mel + OKT3 | 12 |
| TBI (4 Gy) + Amsa + Flu + Cyt ± Cyc ± Bus ± ATG | 7 |
| Other | 5 |
| Number of study patients | 71 |
| Median age, y (range) | 8.0 (0.6-23.1) |
| Median follow-up after transplantation, y (range) | 1.5 (0.1-4.3) |
| Disease status xabefore transplantation, n | |
| CR1 | 23 |
| CR2 | 29 |
| CR > 2 | 2 |
| NR | 17 |
| Donor, n | |
| MSD | 23 |
| MUD | 31 |
| MMFD | 17 |
| Stem-cell source, n | |
| BM | 45 |
| PB | 23 |
| Other | 3 |
| T-cell depletion, n | |
| Yes | 15 |
| No | 56 |
| Myeloablative conditioning regimen, n | |
| Busulfan-based | |
| Bus + Cyc + Mel ± ATG, n | 34 |
| Bus + Cyc ± ATG | 9 |
| Other (TBI/treosulfan-based) | 4 |
| RIC, n | |
| Flu + Thio + Mel + OKT3 | 12 |
| TBI (4 Gy) + Amsa + Flu + Cyt ± Cyc ± Bus ± ATG | 7 |
| Other | 5 |
Amsa indicates amsacrine; ATG, antithymocyte globulin; Bus, busulfan; Cyc, cyclophosphamide; Cyt, cytarabine; Flu, fludarabine; OKT3, anti-CD3 mAb; Mel, melphalan; TBI, total body irradiation; and Thio, thiotepa.